Search

Displaying results 2941 - 2950 of 8411 in total
  1. Drug

    Hexafluronium

    go.drugbank.com/drugs/DB00941
    Approved

    Hexafluronium bromide is a neuromuscular blocking agent used in anesthesiology to prolong and potentiate the skeletal muscle relaxing action of suxamethonium during surgery. It is known to bind and block the activity of plasma cholineste...

  2. Drug

    Sodium lauryl sulfoacetate

    go.drugbank.com/drugs/DB13157
    ApprovedWithdrawn

    Sodium lauryl sulfoacetate is a wetting agent and surfactant used in enema-type laxative products.

  3. Drug

    Methylphenobarbital

    go.drugbank.com/drugs/DB00849
    Approved

    A barbiturate that is metabolized to phenobarbital. It has been used for similar purposes, especially in epilepsy, but there is no evidence mephobarbital offers any advantage over phenobarbital.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Inducers
  4. Drug

    Lymecycline

    go.drugbank.com/drugs/DB00256
    ApprovedInvestigationalWithdrawn

    Lymecycline is a broad-spectrum second-generation tetracycline antibiotic used for the treatment of acne and other susceptible bacterial infections. It has been proven a cost-effective alternative to treatment with minocycline with compa...

  5. Drug

    Dronedarone

    go.drugbank.com/drugs/DB04855
    ApprovedInvestigational

    Dronedarone is a Class III antiarrhythmic drug that works to restore the normal sinus rhythm in patients with paroxysmal or persistent atrial fibrillation. Atrial fibrillation is a common sustained arrhythmia where the treatment primaril...

    Synonyms: N-(2-butyl-3-(p-(3-(dibutylamino)propoxy)benzoyl)-5-benzofuranyl)methanesulfonamideCategories: P-glycoprotein inhibitors, Cytochrome P-450 Substrates
  6. Drug

    Polatuzumab vedotin

    go.drugbank.com/drugs/DB12240
    ApprovedInvestigational

    Polatuzumab vedotin is a CD79b-directed antibody-drug conjugate that delivers monomethyl auristatin E (MMAE), an anti-mitotic agent, to cancer cells. … consists of three components - a humanized immunoglobulin G1 (IgG1) monoclonal antibody specific for human CD79b (polatuzumab), MMAE, and protease-cleavable linker called maleimidocaproyl-valine-citrulline-p-aminobenzyloxycarbonyl

    Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates
  7. Drug

    Ioversol

    go.drugbank.com/drugs/DB09134
    ApprovedInvestigational

    [L41780] Ioversol is a highly hydrophilic agent considered to be generally safe[L41790]; however, serious adverse reactions have been reported due to the inadvertent intrathecal administration of ioversol

  8. Drug

    Bebtelovimab

    go.drugbank.com/drugs/DB16755
    ApprovedWithdrawn

    [L43827] On November 30, 2022, the EUA for bebtelovimab was officially withdrawn due to a lack of efficacy against Omicron subvariants, therefore bebtelovimab is no longer authorized for emergency use … [L40328] Bebtelovimab was issued an emergency use authorization (EUA) by the FDA on February 11, 2022, for the treatment of mild-to-moderate COVID-19 in select patients.

  9. Drug

    Umifenovir

    go.drugbank.com/drugs/DB13609
    Investigational

    Umifenovir is an indole-based, hydrophobic, dual-acting direct antiviral/host-targeting agent used for the treatment and prophylaxis of influenza and other respiratory infections.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Substrates
  10. Drug

    Menadione

    go.drugbank.com/drugs/DB00170
    ApprovedNutraceutical

    A synthetic naphthoquinone without the isoprenoid side chain and biological activity, but can be converted to active vitamin K2, menaquinone, after alkylation in vivo.

    Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 CYP1A2 Inhibitors